These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35135308)

  • 1. MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.
    Haeusler KG; Eichner FA; Heuschmann PU; Fiebach JB; Engelhorn T; Blank B; Callans D; Elvan A; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Mont L; Nielsen JC; Piccini JP; Schotten U; Themistoclakis S; Vijgen J; Di Biase L; Kirchhof P
    Circulation; 2022 Mar; 145(12):906-915. PubMed ID: 35135308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of brain lesions after catheter ablation depends on imaging criteria: insights from AXAFA-AFNET 5 trial.
    Haeusler KG; Eichner FA; Heuschmann PU; Fiebach JB; Engelhorn T; Callans D; De Potter T; Debruyne P; Scherr D; Hindricks G; Al-Khalidi HR; Mont L; Kim WY; Piccini JP; Schotten U; Themistoclakis S; Di Biase L; Kirchhof P
    Europace; 2023 Dec; 25(12):. PubMed ID: 37897713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study.
    Herm J; Fiebach JB; Koch L; Kopp UA; Kunze C; Wollboldt C; Brunecker P; Schultheiss HP; Schirdewan A; Endres M; Haeusler KG
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):843-50. PubMed ID: 23989301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study.
    Chen WJ; Gan CX; Cai YW; Liu YY; Xiao PL; Zou LL; Xiong QS; Qin F; Tao XX; Li R; Du HA; Liu ZZ; Yin YH; Ling ZY
    BMC Med; 2023 Nov; 21(1):461. PubMed ID: 37996906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Kirchhof P; Haeusler KG; Blank B; De Bono J; Callans D; Elvan A; Fetsch T; Van Gelder IC; Gentlesk P; Grimaldi M; Hansen J; Hindricks G; Al-Khalidi HR; Massaro T; Mont L; Nielsen JC; Nölker G; Piccini JP; De Potter T; Scherr D; Schotten U; Themistoclakis S; Todd D; Vijgen J; Di Biase L
    Eur Heart J; 2018 Aug; 39(32):2942-2955. PubMed ID: 29579168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation　- Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging.
    Nakamura K; Naito S; Sasaki T; Minami K; Take Y; Goto E; Shimizu S; Yamaguchi Y; Suzuki N; Yano T; Senga M; Kumagai K; Kaseno K; Funabashi N; Oshima S
    Circ J; 2016; 80(4):870-7. PubMed ID: 26888266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation.
    Zink MD; Chua W; Zeemering S; di Biase L; Antoni BL; David C; Hindricks G; Haeusler KG; Al-Khalidi HR; Piccini JP; Mont L; Nielsen JC; Escobar LA; de Bono J; Van Gelder IC; de Potter T; Scherr D; Themistoclakis S; Todd D; Kirchhof P; Schotten U
    Europace; 2020 Sep; 22(9):1337-1344. PubMed ID: 32725107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry.
    Di Biase L; Briceno DF; Trivedi C; Mohanty S; Gianni C; Burkhardt JD; Mohanty P; Bai R; Gunda S; Horton R; Bailey S; Sanchez JE; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Reddy YM; Zagrodzky J; Hongo R; Beheiry S; Lakkireddy D; Natale A
    Heart Rhythm; 2016 Jun; 13(6):1197-202. PubMed ID: 26994940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.
    Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A
    Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
    Mao YJ; Wang H; Huang PF
    J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Holmqvist F; Simon D; Steinberg BA; Hong SJ; Kowey PR; Reiffel JA; Naccarelli GV; Chang P; Gersh BJ; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2015 May; 4(5):. PubMed ID: 25999401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study.
    Haeusler KG; Koch L; Herm J; Kopp UA; Heuschmann PU; Endres M; Schultheiss HP; Schirdewan A; Fiebach JB
    J Cardiovasc Electrophysiol; 2013 Jan; 24(1):14-21. PubMed ID: 22913568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial.
    Verma A; Debruyne P; Nardi S; Deneke T; DeGreef Y; Spitzer S; Balzer JO; Boersma L;
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):835-42. PubMed ID: 23983245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Incidence of Asymptomatic Cerebral Emboli After Atrial Fibrillation Ablation Found With High-Resolution Diffusion-Weighted Magnetic Resonance Imaging.
    Yu Y; Wang X; Li X; Zhou X; Liao S; Yang W; Yu J; Zhang F; Ju W; Chen H; Yang G; Li M; Gu K; Tang L; Xu Y; Chan JY; Kojodjojo P; Cao K; Fan J; Yang B; Chen M
    Circ Arrhythm Electrophysiol; 2020 Jan; 13(1):e007548. PubMed ID: 31937118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
    Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
    J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.